892549-58-5

Basic information

• Product Name: C₂₈H₁₇ClN₄O
• Synonyms: C₂₈H₁₇ClN₄O
• CAS NO: 892549-58-5
• Molecular Weight: 460.922
• Mol File: 892549-58-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: C₂₈H₁₇ClN₄O(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₈H₁₇ClN₄O(892549-58-5)
• EPA Substance Registry System: C₂₈H₁₇ClN₄O(892549-58-5)

Safety Data

• Hazardous Substances Data: 892549-58-5(Hazardous Substances Data)

Upstream product

• 892549-54-1 2-[9-chloro-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile 
• 115-19-5 2-methyl-but-3-yn-2-ol 
• 1193719-23-1 6-bromo-3-chlorophenanthrene-9-carboxylic acid 
• 938070-94-1 9-bromo-6-chloro-2-(2,6-dibromophenyl)-1H-phenanthro[9,10-d]imidazole acetic acid salt 
• 892550-46-8 9-bromo-6-chloro-2-(2,6-dibromophenyl)-1H-phenanthro[9,10-d]imidazole 
• 122-01-0 4-chloro-benzoyl chloride 
• 57082-98-1 (E)-1-bromo-4-(4-chlorostyryl)benzene 
• 7461-38-3 4-chloro-N,N-diethyl-benzamide 
• 5551-11-1 4-Chloro-2-nitrobenzaldehyde 
• 937053-63-9 6-chloro-phenanthren-9-ol 
• 892550-47-9 (2E)-2-(4-bromophenyl)-3-(4-chloro-2-nitrophenyl)acrylic acid 
• 892550-48-0 (2E)-3-(2-amino-4-chlorophenyl)-2-(4-bromophenyl)acrylic acid 

Downstream Products

• 892550-41-3 (+/-)-2-[9-chloro-6-(3,4-dihydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile 
• 892549-54-1 2-[9-chloro-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile 
• 892550-54-8 2-[6-chloro-9-(3-methylbut-3-en-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]isophthalonitrile 

Relevant articles and documents

Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors

Phenanthrene imidazoles 26 and 44 have been identified as novel potent, selective and orally active mPGES-1 inhibitors. These inhibitors are significantly more potent than the previously reported chlorophenanthrene imidazole 1 (MF63) with a human whole blood IC50 of 0.20 and 0.14 μM, respectively. It exhibited a significant analgesic effect in a guinea pig hyperalgesia model at oral doses as low as 14 mg/kg. Both active and selective mPGES-1 inhibitors (26 and 44) have a relatively distinct pharmacokinetic profile and are suitable for clinical development. Crown Copyright

2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS

The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed

METHODS FOR TREATING OR PREVENTING NEOPLASIAS

The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.